Merck's (MRK) new drug application for gefapixant to treat refractory chronic cough or unexplained chronic cough fails to secure approval from the FDA. Meanwhile, the drug secures approval in Japan.
Regeneron (REGN) is expected to maintain momentum on the back of a solid and diverse portfolio. The promising pipeline also sets the stage for further growth.
Dare (DARE) gets FDA approval for Xaciato (clindamycin phosphate) vaginal gel as a treatment for bacterial vaginosis.